MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy

Details for Australian Patent Application No. 2005237256 (hide)

Owner GlaxoSmithKline Biologicals S.A.

Inventors Brichard, Vincent; Meaders, Melinda; Palmantier, Remi M; Bruck, Claudine Elvire Marie

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005237256

PCT Pub. Number WO2005/105139

Priority 0409940.4 04.05.04 GB

Filing date 2 May 2005

Wipo publication date 10 November 2005

International Classifications

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61K 39/39 (2006.01) Medicinal preparations containing antigens or antibodies - characterised by the immunostimulating additives, e.g. chemical adjuvants

Event Publications

9 November 2006 PCT application entered the National Phase

  PCT publication WO2005/105139 Priority application(s): WO2005/105139

25 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005237266-Pharmaceutical compositions

2005237255-Management of breakthrough bleeding in extended hormonal contraceptive regimens